SEC Form 4 · accession 0001209191-19-008582
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 4:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 6, 2019 | A | 53,816 | $0.00 | A | 178,681 | D | |
| Common StockF2 | Feb 6, 2019 | A | 31,498 | $0.00 | A | 210,179 | D | |
| Common StockF3 | Feb 6, 2019 | A | 28,444 | $0.00 | A | 238,623 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $187.53 | Feb 6, 2019 | A | 72,647 | A | — | Feb 5, 2029 | Common Stock | 72,647 | 72,647 | D |
Explanation of responses
- F1Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019 and the shares will vest on 2/10/2019.
- F2Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019.
- F3Restricted stock unit award that vests in installments beginning on 2/24/2020.
- F4The option vests in 16 quarterly installments from 02/6/2019.